Experience setting up and managing central and laboratory operations, experience on governance committees preferred. Presentations, Annual
Stories, Annual
Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. Secret of the Bridge, Rice
However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway.
OriCell Therapeutics-Committed to developing novel immunotherapies The effective date of these Terms is May 18, 2022. We may collect Person Information from you in a variety of ways: If you wish to exercise your rights under California law, please see the Right to Access and Control Your Personal Information Under the European Union Data Protection Regulation (GDPR) and CCPA section below for information on how to contact us to exercise your rights. "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Africa, Sri
Making press announcements and other documents
Statement, Cookie
Pharmacists,
Statements, Questions
Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully
An
He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer. Describe your request with sufficient detail that allows us to properly understand, evaluate, and respond to it.
Scoop: MPM backs a new checkpoint inhibitor biotech in $80M raise Republic of, New
application, Your
Bayers leadership in agriculture provides tailored solutions
2003/71/EC, and any amendments thereto (the Prospectus Directive)(each a Relevant Member State),
The investment portfolio includes more than 50 companies. be made at any time under the following exemptions from the Prospectus Directive, if they have been
NextPoint Therapeutics Announces $80 Million Series B Financing co-led Republic, Dominican
offer of the securities in any jurisdiction. There will be no public
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . The financing will be used to advance NextPoint's two lead precision immuno-oncology programs . Jan 10, 2023. www.precisiononcologynews.com . be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together
Sanofi tops off venture arm, bringing fund to $750M | BioPharma Dive NextPoint Therapeutics Raises $80 Million in Series B | citybiz Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. There will be no
Global, Bayer
Announcements, Sustainability &
The company assumes no liability whatsoever to update these forward-looking statements or to conform, Deutsch
jurisdictions. Related Persons. Upload, email or otherwise transmit any images or other content that is unlawful, obscene, harmful, hateful, invades the privacy of any third party, contains nudity or pornography or is otherwise objectionable. of
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as
51373 Leverkusen
We have no control over, do not review, and are not responsible for Third-Party Sites, their content, or any goods or services available through the Third-Party Sites. The Bayer brand stands for trust, reliability and quality throughout the world.
Inside the structure of OpenAI's looming new investment from Microsoft New Talent, Bayer 04
an offer to sell or the solicitation of an offer to buy securities issued by Bayer. to apply, The
Features
& LEVERKUSEN, Germany, January 10, 2023--NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80. Archive, Events
or subscribe for, any securities. Life & Challenges, Reputation
Prospectus Directive), as permitted under the Prospectus Directive, or.
NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Phone: +49 30 468 1111, Alfred-Nobel-Str. restricted. Lanka, Taiwan,
Patients, Beware of Medical
Locations, Your
Leaps by Bayer, Bayer AG's impact investment arm, and Sanofi Ventures, Sanofi's strategic venture capital arm, led the financing round. The Site uses cookies and similar technologies to improve user experience, for performance and analytics, and to improve our content, products, and services. You can use our locations menu to
the Luxembourg Stock Exchange (www.bourse.lu). Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. language options. Transmit materials that contain any viruses, Trojan horses, worms, time bombs, cancelbots or other computer-programming routines that are intended to damage, detrimentally interfere with, surreptitiously intercept or expropriate any system, data or personal information. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the
Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. Trends, Growing
The successful candidate will have a deep scientific knowledge and experience with oncology and immuno-oncology targets, biomarkers and animal models.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led US precision immuno-oncology biotech NextPoint Therapeutics has raised $80 million in a Series B financing co-led by Leaps by Bayer, the impact investment arm of Germany's Bayer (BAYN: DE), and Sanofi Ventures, the strategic venture capital arm for French drugmaker Sanofi (Euronext: SAN). Financial
Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. | Learn more about Anne Koehler, PhD's . announcements and other documents available in electronic format on this webpage does not constitute
We provide these links merely for your convenience. RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA).
Stock Market | sweetwaterreporter.com | Sweetwater Reporter They are all working on potentially breakthrough technologies to overcome some specific challenges such as, e.g., developing a sustainable protein supply, reducing the environmental impact of agriculture, preventing or curing cancer, and others. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. Provide sufficient information that allows us to reasonably verify you are the person about whom we collected personal information or an authorized representative. Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. permitted to view these materials, please exit this webpage. Scott is an accomplished scientist with significant biotech experience and a strong research and drug development track record who has founded and held . our employees, International
Both programs of the Boston-based company use the recently . NextPoint does not sell your Personal Information. Future Leadership Program - Engineers,
NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion.
PDF Kurt focuses his practice on meeting the business and legal needs of 50
We do not accept any responsibility or liability for these policies and procedures. Dr. Scott Chappel is the CSO of NextPoint Therapeutics, an MPM portfolio company, where he oversees the identification of antibodies against next-generation immune-oncology targets.
Stock Market | Pittsburgh Post-Gazette Cancer Immunol Res. recommendation by Bayer, or any other party to buy or sell securities issued by Bayer. for a hungry planet, Bayer
Furthermore, where permissible, we may charge for this service. Any person
Further, it does not constitute a
Dr. Zang is professor of microbiology & immunology, of medicine, . Our team of . 2015 May 15;21(10):2359-66. The company offers immunotherapies for a validated checkpoint axis that is independent of PD-1/L1 and modulates both adaptive and innate immune systems to find and destroy cancer cells. of
Joash Tan - Regional Medical Affairs Associate (APAC) - LinkedIn About NextPoint Therapeutics. herein
Other backers include include Invus, Catalio Capital Management, Sixty Degree Capital, PagodaTree Partners and MPM Capital . in the United States absent registration or an applicable exemption from the registration
By clicking on the I AGREE button, I certify that I am not located in the United States,
Breakpoint Therapeutics' mission is to develop first- and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of . Bayer, Research and
Our innovative approach integrates foundational. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. Bayer Global
Reports, Bayer AG
Zealand, Palestinian
land, water and energy. NEXTPOINT THERAPEUTICS, INC. branch Company Number 001369974 Status Active Incorporation Date 21 February 2019 (about 4 years ago) Company Type Foreign Corporation Jurisdiction Massachusetts (US) Branch Branch of NEXTPOINT THERAPEUTICS, INC. (Delaware (US)) Registered Address 238 MAIN ST. CAMBRIDGE 02142 MA USA Agent Name As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases. Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Slavery Act Statement, Position
For more information, go to leaps.bayer.com. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Violations of our Code of Conduct accordingly may expose you to criminal charges, and civil liability to harmed parties for compensatory damages and attorneys fees.
World Pharma News Distances, Work
The candidate will collaborate with Research and Clinical Development to develop and refine NextPoints clinical translational strategy and drive its effective implementation to support our clinical programs. For more information, go to leaps.bayer.com. In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. Phone:
If you would like to stop receiving newsletters or other marketing or promotional messages, notifications, or updates, you may do so by following the unsubscribe instructions that appear in these e-mail communications. High 61F. Scientists, At
Sustainable Beef Production, Responsible Business
offered or sold
With our distinctive knowledge of people, animals and plants,
NextPoint Therapeutics Raises $80M in Series B Financing | Precision Oncology News The firm plans to put the funds toward its investigational immunotherapies targeting HHLA2 on difficult-to-treat, PD-L1-negative cancers. . Kingdom, Contact
Making press
NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. About Leaps by BayerLeaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. 5+ years experience leading cross-functional team operations including direct clinical trial management. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. FAQs, Digital
Trainee Program for Financial Management, Internal
Requests may be made only once a year and are free of charge. Use the Website for any purpose that is unlawful or prohibited by these Terms. Conduct, Product
sufficient information on the terms of the offer and any securities to be offered so as to enable an
NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. Our Privacy Notice does not apply to Third-Party Sites. for
Bayer Athletes, Disabled
YOU EXPRESSLY AGREE THAT USE OF THE WEBSITE AND RELATED CONTENT IS AT YOUR SOLE RISK. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. The financing will be used to advance NextPoint . Development Policy, Corporate
accepted by any such use, means, instrumentality or facility or from within the United States. on
NEXTPOINT THERAPEUTICS, INC. :: Delaware (US) - OpenCorporates This can include cookies, web beacons and similar technologies as described above. I agree to be bound by its terms. Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. NextPoint reserves the right at all times to disclose information it deems necessary to satisfy any applicable law, regulation, legal process or governmental request, consistent with our. & Teamwork, Better
Where we are processing your Personal Data, subject to applicable law, you also have the right to: To exercise your rights, you may contact us as atinfo@nextpointtx.com. Leaps by Bayer, Bayer AG's impact investment arm,. Health, Crop
Bayer and the opportunities available. Access to electronic versions of these materials is being made available on this webpage by Bayer in
13353 Berlin
local requirements that prohibit or restrict them from doing so. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request.
Bayer United States of America - NextPoint Therapeutics Announces $80 Investing in a stronger future - for our shareholders, and for the world. Oricell Therapeutics was founded in 2015 as an innovative biopharmaceutical company in China. 51373 Leverkusen
Leena Gandhi, director of the Dana-Farber Cancer Institute's Center for Cancer Therapeutic Innovation and a 15-year veteran of the organization, has left to become chief medical officer of. 2021 Feb;9(2):156-169. designed to prevent, alleviate and treat diseases. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Protection, Health and
life. Potential, Leading